Outcome following URD BMT for CML: multivariate analysis
| A. Graft failure (n = 137) . | B. Grade III/IV acute GVHD (n = 566) . | ||||
|---|---|---|---|---|---|
| . | RR (95% CI) . | P . | . | RR (95% CI) . | P . |
| Chronic phase TBI conditioning Younger recipient* Unmanipulated graft HLA-match Year of BMT 1988-90 1991-93 1994-96 Marrow cell dose† 2.0 2.1-3.99 4.0 | 0.63 (0.44-0.92) 0.30 (0.20-0.46) 0.89 (0.61-1.29) 1.18 (.71-1.92) 0.68 (.43-1.08) 1.0 0.79 (0.45-1.37) 0.78 (0.44-1.37) 1.0 0.63 (0.40-1.0) 0.50 (0.26-0.94) | .015 .0001 .54 .52 .01 .04 .38 .05 .03 | Chronic phase TBI conditioning Younger recipient* T-depletion HLA-match Early BMT‡ Donor parity | 0.68 (0.55-0.83) 0.96 (0.68-1.34) 0.91 (0.74-1.11) 0.58 (0.42-0.81) 0.64 (0.50-0.81) 0.86 (0.68-1.09) 0.97 (0.71-1.33) | .0002 .80 .34 .0012 .0003 .21 .85 |
| C. Chronic GVHD (extensive) (n = 510) | D. Leukemia relapse (n = 123) | ||||
| RR (95% CI) | P | RR (95% CI) | P | ||
| Chronic phase TBI conditioning Younger recipient* T-depletion HLA-match Early BMT‡ | 0.70 (0.56-0.86) 0.79 (0.57-1.10) 0.94 (0.78-1.13) 0.64 (0.46-0.89) 0.91 (0.70-1.16) 0.88 (0.72-1.07) | .0004 .16 .51 .008 .45 .19 | Chronic phase TBI conditioning Younger recipient* Unmanipulated graft HLA-match Early BMT‡ Grade 0-II acute GVHD Chronic GVHD | 0.14 (0.09-0.23) 0.78 (0.34-1.75) 0.82 (0.53-1.25) 0.41 (0.22-0.78) 0.80 (0.47-1.35) 1.11 (0.70-1.76) 1.25 (0.76-2.08) 0.91 (0.54-1.51) | .0001 .54 .35 .005 .41 .67 .37 .70 |
| A. Graft failure (n = 137) . | B. Grade III/IV acute GVHD (n = 566) . | ||||
|---|---|---|---|---|---|
| . | RR (95% CI) . | P . | . | RR (95% CI) . | P . |
| Chronic phase TBI conditioning Younger recipient* Unmanipulated graft HLA-match Year of BMT 1988-90 1991-93 1994-96 Marrow cell dose† 2.0 2.1-3.99 4.0 | 0.63 (0.44-0.92) 0.30 (0.20-0.46) 0.89 (0.61-1.29) 1.18 (.71-1.92) 0.68 (.43-1.08) 1.0 0.79 (0.45-1.37) 0.78 (0.44-1.37) 1.0 0.63 (0.40-1.0) 0.50 (0.26-0.94) | .015 .0001 .54 .52 .01 .04 .38 .05 .03 | Chronic phase TBI conditioning Younger recipient* T-depletion HLA-match Early BMT‡ Donor parity | 0.68 (0.55-0.83) 0.96 (0.68-1.34) 0.91 (0.74-1.11) 0.58 (0.42-0.81) 0.64 (0.50-0.81) 0.86 (0.68-1.09) 0.97 (0.71-1.33) | .0002 .80 .34 .0012 .0003 .21 .85 |
| C. Chronic GVHD (extensive) (n = 510) | D. Leukemia relapse (n = 123) | ||||
| RR (95% CI) | P | RR (95% CI) | P | ||
| Chronic phase TBI conditioning Younger recipient* T-depletion HLA-match Early BMT‡ | 0.70 (0.56-0.86) 0.79 (0.57-1.10) 0.94 (0.78-1.13) 0.64 (0.46-0.89) 0.91 (0.70-1.16) 0.88 (0.72-1.07) | .0004 .16 .51 .008 .45 .19 | Chronic phase TBI conditioning Younger recipient* Unmanipulated graft HLA-match Early BMT‡ Grade 0-II acute GVHD Chronic GVHD | 0.14 (0.09-0.23) 0.78 (0.34-1.75) 0.82 (0.53-1.25) 0.41 (0.22-0.78) 0.80 (0.47-1.35) 1.11 (0.70-1.76) 1.25 (0.76-2.08) 0.91 (0.54-1.51) | .0001 .54 .35 .005 .41 .67 .37 .70 |
BMT = bone marrow transplant; CML = chronic myelogenous leukemia; GVHD = graft-versus-host disease; RR = relative risk; TBI = total body irradiation; URD = unrelated donor.
Cox multivariate regression analysis demonstrating the relative risk (RR) (95% confidence interval [CI]) of clinical end points shown. Favorable factors associated with protection against the stated endpoint are shown. In panel C, prior acute or chronic GVHD were entered as time-dependent variables. Only hematologic relapse was considered in panel D.
No older than 35 years.
×108 nucleated cells/kg recipient weight.
<12 months from diagnosis.